Rafał Stec1, Lubomir Bodnar, Cezary Szczylik. 1. Department of Oncology, Military Institute of the Health Services in Warsaw, Szaserów 128 Str., 00-909, Warsaw, Poland, drrafals@wp.pl.
Abstract
PURPOSE: A retrospective analysis was conducted to compare the tolerability and efficacy of single-agent capecitabine and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) in the first-line treatment of patients aged > or =65 years with metastatic colorectal cancer (mCRC). METHODS: Consecutive patients with mCRC treated at the Military Medical Institute, Warsaw, between January 2003 and June 2008 were eligible. A total of 123 patients were identified (FOLFIRI, n = 67; capecitabine, n = 56). RESULTS: The overall response rate with FOLFIRI was 28.1 versus 16.4% with capecitabine (P = 0.1398). Median time to disease progression with FOLFIRI was 8.8 versus 7.5 months with capecitabine (P = 0.20), and median overall survival was 19.0 versus 15.4 months (P = 0.93). In the FOLFIRI group, neutropenia and anaemia were significantly more frequent than in the capecitabine group. The main non-haematological toxicity was hand-foot syndrome found only in the capecitabine group. CONCLUSION: Single-agent capecitabine and FOLFIRI are effective first-line regimens in patients aged > or =65 years with mCRC.
PURPOSE: A retrospective analysis was conducted to compare the tolerability and efficacy of single-agent capecitabine and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) in the first-line treatment of patients aged > or =65 years with metastatic colorectal cancer (mCRC). METHODS: Consecutive patients with mCRC treated at the Military Medical Institute, Warsaw, between January 2003 and June 2008 were eligible. A total of 123 patients were identified (FOLFIRI, n = 67; capecitabine, n = 56). RESULTS: The overall response rate with FOLFIRI was 28.1 versus 16.4% with capecitabine (P = 0.1398). Median time to disease progression with FOLFIRI was 8.8 versus 7.5 months with capecitabine (P = 0.20), and median overall survival was 19.0 versus 15.4 months (P = 0.93). In the FOLFIRI group, neutropenia and anaemia were significantly more frequent than in the capecitabine group. The main non-haematological toxicity was hand-foot syndrome found only in the capecitabine group. CONCLUSION: Single-agent capecitabine and FOLFIRI are effective first-line regimens in patients aged > or =65 years with mCRC.
Authors: P M Hoff; R Ansari; G Batist; J Cox; W Kocha; M Kuperminc; J Maroun; D Walde; C Weaver; E Harrison; H U Burger; B Osterwalder; A O Wong; R Wong Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper Journal: J Clin Oncol Date: 2001-11-01 Impact factor: 44.544
Authors: Christian Weissenberger; Michael Geissler; Florian Otto; Annette Barke; Karl Henne; Georg von Plehn; Alex Rein; Christine Muller; Susanne Bartelt; Michael Henke Journal: World J Gastroenterol Date: 2006-03-28 Impact factor: 5.742
Authors: L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245
Authors: F Lagautrière; L Valvano; M Chaazl; D Benchimol; J L Bernard; A Bourgeon; H Richelme Journal: Ann Ital Chir Date: 1998 Jul-Aug Impact factor: 0.766
Authors: J Cassidy; C Twelves; E Van Cutsem; P Hoff; E Bajetta; M Boyer; R Bugat; U Burger; A Garin; U Graeven; J McKendric; J Maroun; J Marshall; B Osterwalder; G Pérez-Manga; R Rosso; P Rougier; R L Schilsky Journal: Ann Oncol Date: 2002-04 Impact factor: 32.976